Metabolic
Oral GLP-1 receptor agonist for type 2 diabetes and weight management
Orforglipron is indicated for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. As the first oral non-peptide GLP-1 receptor agonist, it offers a convenient daily pill alternative to injectable therapies.
Orforglipron is a novel non-peptide GLP-1 receptor agonist that mimics the action of the naturally occurring incretin hormone GLP-1. It binds to and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways.
Treatment is initiated at a low dose and gradually titrated upward. The typical maintenance dose ranges from 24 mg to 36 mg taken orally once daily. Dose adjustments are made based on glycemic response and tolerability.